Latest News and Press Releases

Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financingDebuted as...

Alvotech releases ESG indicators covering both 2020 and 2021 Carbon neutrality for scope 1 and 2 emissions achieved in 2020 and 2021ESG portal is now available on the Company’s website at...

Alvotech releases ESG indicators covering both 2020 and 2021 Carbon neutrality for scope 1 and 2 emissions achieved in 2020 and 2021ESG portal is now available on the Company’s website at...

Alvotech birtir gögn um um mælikvarða tengda árangri í umhverfismálum, félagslegum þáttum og stjórnarháttum (e. ESG) fyrir árin 2020 og 2021.Starfsemin var kolefnishlutlaus árin 2020 og 2021 að teknu...

Alvotech has now entered four biosimilar candidates into confirmatory patient studiesCombined sales of Prolia® and Xgeva® (denosumab) which are used to treat bone diseases were nearly $5.3...

Alvotech hefur nú hafið eða lokið klínískum rannsóknum á fjórum líftæknilyfjahliðstæðumProlia® og Xgeva® (denosumab) eru lyf við sjúkdómum í beinum og námu tekjur af sölu þeirra um 740 milljörðum...

Alvotech has now entered four biosimilar candidates into confirmatory patient studiesCombined sales of Prolia® and Xgeva® (denosumab) which are used to treat bone diseases were nearly $5.3 billion in...

Alvotech tilkynnti í dag þátttöku í tveimur fjárfestaráðstefnum í september 2022. Fulltrúar úr yfirstjórn Alvotech munu kynna fyrirtækið og sitja fyrir svörum: Á 17. árlegu ráðstefnu Citi um...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team...

REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for...